A Big Acquisition, Poised for Nasdaq and a Zacks $25.50 Target! ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏




 

_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Huge Alerts._

 

-------------------------

BioStem Technologies (OTCQB: BSEM) Accelerates Into 2026 With a
Transformational Acquisition, Expanding Its Reach Across Advanced and
Acute Wound Care!

 [BSEM] [[link removed]]

Seven Profitable Quarters, a $29M Revenue Acquisition, Entry into
Hospital-Based Care, and a Potential Nasdaq Uplisting Position BSEM as
One of the Most Compelling Small-Cap MedTech Stories to Watch This
Year.

Greetings All,

The medical technology sector sits at the intersection of innovation,
necessity, and scale—making it one of the most durable long-term
investment themes in global markets. Aging populations, rising rates
of chronic disease, and persistent demand for healthcare services
continue to support spending regardless of economic cycles.

As 2026 begins, MedTech stands out not just for its resilience, but
for its evolution. Healthcare systems are increasingly prioritizing
outcomes-driven solutions, cost efficiency, and technologies that can
reduce hospital stays, complications, and long-term care burdens.
Within this landscape, companies that combine clinical proof,
reimbursement access, and profitability are separating quickly from
the pack.

One small-cap name increasingly fitting that profile is BioStem
Technologies, Inc. (OTCQB: BSEM).
[[link removed]]

Breaking News: BioStem Enters Advanced & Acute Wound Care With
Transformational Acquisition

BSEM kicked off 2026 with a major strategic milestone, announcing the
completion of its acquisition of BioTissue Holdings’ surgical and
wound care business—a move that significantly expands BioStem’s
footprint beyond chronic wounds and into advanced, acute, and
hospital-based wound care.

The acquisition brings well-established product lines—including
Neox® and Clarix®—along with a nationwide commercial sales force,
independent sales agents, and existing GPO contracts that provide
immediate access to hospital inpatient and outpatient settings. 

The acquired business generated approximately $29 million in revenue
in 2025 and is expected to contribute positive EBITDA in 2026,
accelerating BioStem’s growth while diversifying its revenue
streams.

Strategically, this deal does more than add revenue. It creates a
direct pathway into high-value segments such as surgical wounds,
burns, trauma, and soft-tissue repair—markets that significantly
expand BSEM’s total addressable opportunity. With this move, BSEM
now spans the full continuum of wound care, from chronic conditions to
acute surgical applications, a capability rarely seen among small-cap
regenerative medicine companies.

Financial Performance: Profitable Where Most Peers Still Burn Cash

BSEM continues to distinguish itself financially. The company has now
delivered seven consecutive profitable quarters, an uncommon
achievement in regenerative medicine and small-cap MedTech.

In its most recent quarter, BSEM reported:

*
$10.5 million in revenue

*
$0.8 million in GAAP net income

*
$2.7 million in adjusted EBITDA

*
88.5% gross margins

Following the BioTissue transaction, BSEM ended the period with
approximately $16 million in cash and restricted cash, reflecting both
disciplined capital allocation and the ability to fund growth without
shareholder dilution. This financial consistency reinforces that BSEM
is operating a scalable commercial model—not an early-stage science
experiment.

Technology Edge: BioREtain® Delivers Level 1 Clinical Validation

At the core of BioStem’s competitive advantage is its proprietary
BioREtain® processing technology, designed to preserve the natural
structure and growth-factor composition of placental tissue.

That differentiation is supported by rare clinical proof. In a Level 1
randomized controlled trial for diabetic foot ulcers, BSEM’s product
demonstrated a 53% probability of complete wound closure, compared to
just 31% under standard of care. 

Conducted under FDA-level rigor and published in a peer-reviewed
journal, the data validates BioStem’s claims and strengthens its
position with physicians, payors, and healthcare systems.

In an environment increasingly focused on value-based care and
measurable outcomes, this level of clinical validation is a powerful
adoption driver.

Market Opportunity: A $300M+ Runway with Expanding Access

The economic burden of chronic wounds remains enormous. Diabetic foot
ulcers alone cost the U.S. healthcare system an estimated $9–$13
billion annually, driven by infections, hospitalizations, and
amputations.

BSEM has already expanded into high-value channels including:

*
The Department of Veterans Affairs

*
State Medicaid programs, including Texas

*
Hospitals and ambulatory surgery centers

With the addition of BioTissue’s surgical and acute wound portfolio,
management now estimates a $300–$350 million addressable market.
Early traction supports that outlook, as BSEM reported 40%
year-over-year growth in unit volumes, even amid pricing pressure
across the sector.

Upcoming Catalyst: Nasdaq Uplisting in Focus for 2026

Looking ahead, BSEM is actively targeting a Nasdaq uplisting in
mid-2026, following completion of KPMG audits and continued engagement
with the SEC. A successful uplisting could meaningfully increase
liquidity, unlock institutional ownership, and allow BioStem to be
valued alongside listed MedTech peers rather than remaining
constrained to the OTC market.

With FDA-registered and AATB-accredited manufacturing, a growing
patent portfolio, national reimbursement coverage, sustained
profitability, and now expanded hospital-scale commercial reach, BSEM
is building an increasingly institutional-grade profile.

Analyst Perspective: A $25.50 Target Highlights the Disconnect

That growing profile has not gone unnoticed. Zacks Small Cap Research
has assigned BSEM a $25.50 price target, citing the company’s
profitability, clinical validation, and expanding commercial
footprint.

While reimbursement reform and pricing pressure remain ongoing
industry considerations, BSEM appears well positioned to benefit as
healthcare systems increasingly reward technologies that deliver
proven outcomes and economic value.

The Bottom Line

BioStem Technologies is no longer a speculative regenerative medicine
story. 

With seven straight profitable quarters, breakthrough clinical data, a
transformative expansion into advanced and acute wound care, and a
potential Nasdaq uplisting ahead, BSEM stands out as one of the more
compelling small-cap MedTech companies to watch as 2026 unfolds.

BioStem’s execution-driven trajectory makes it a name worth
following closely this year and beyond
[[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists
of up to $6,500 and was received/will be received from Sideways
Frequency.

This communication should not be considered as an endorsement of the
securities of BioStem Technologies Inc. (OTC: BSEM) and we are not
responsible for any errors or omissions in any information provided
about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge
Alerts.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 02/02/2026.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]


Behind the Markets
[[link removed]]

_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._


TODAY'S BONUS CONTENT: Gold's Next Surge is Imminent
[[link removed]]